Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroshi Handa

Showing results (11-20 of 549) with videos related to

Pageof 55
Sort By:
International Journal of Hematology|July 28, 2016
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugsTakumi Ito, Hiroshi Handa
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|June 12, 2020
Molecular mechanisms of thalidomide and its derivativesTakumi Ito, Hiroshi Handa
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
[Cereblon as a primary target of IMiDs]Takumi Ito, Hiroshi Handa
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2006
[New treatment strategy of multiple myeloma for cure]Hirokazu Murakami, Hiroshi Handa
Seikagaku. the Journal of Japanese Biochemical Society|March 17, 2011
[Molecular mechanism of thalidomide teratogenicity]Takumi Ito, Hiroshi Handa
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|November 21, 2007
[Mechanisms of cell cycle-dependent histone expression]Yuki Yamaguchi, Hiroshi Handa
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|February 28, 2003
[Molecular switch for mRNA synthesis rate]Tadashi Wada, Yuki Yamaguchi, Hiroshi Handa
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 12, 2007
[Diagnosis and management guideline for multiple myeloma]Hirokazu Murakami, Hiroshi Handa, Takayuki Saitoh
Expert Review of Vaccines|February 19, 2013
SV40 virus-like particles as an effective delivery system and its application to a vaccine carrierMasaaki Kawano, Masanori Matsui, Hiroshi Handa
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2013
[I. Proteasome inhibitor for treatment of multiple myeloma]Hirokazu Murakami, Takayuki Saito, Hiroshi Handa
Pageof 55

Showing results (11-20 of 549) with videos related to

Sort By:
Pageof 55
International Journal of Hematology|July 28, 2016
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugsTakumi Ito, Hiroshi Handa
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|June 12, 2020
Molecular mechanisms of thalidomide and its derivativesTakumi Ito, Hiroshi Handa
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 11, 2019
[Cereblon as a primary target of IMiDs]Takumi Ito, Hiroshi Handa
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 14, 2006
[New treatment strategy of multiple myeloma for cure]Hirokazu Murakami, Hiroshi Handa
Seikagaku. the Journal of Japanese Biochemical Society|March 17, 2011
[Molecular mechanism of thalidomide teratogenicity]Takumi Ito, Hiroshi Handa
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|November 21, 2007
[Mechanisms of cell cycle-dependent histone expression]Yuki Yamaguchi, Hiroshi Handa
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|February 28, 2003
[Molecular switch for mRNA synthesis rate]Tadashi Wada, Yuki Yamaguchi, Hiroshi Handa
Nihon Rinsho. Japanese Journal of Clinical Medicine|December 12, 2007
[Diagnosis and management guideline for multiple myeloma]Hirokazu Murakami, Hiroshi Handa, Takayuki Saitoh
Expert Review of Vaccines|February 19, 2013
SV40 virus-like particles as an effective delivery system and its application to a vaccine carrierMasaaki Kawano, Masanori Matsui, Hiroshi Handa
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 21, 2013
[I. Proteasome inhibitor for treatment of multiple myeloma]Hirokazu Murakami, Takayuki Saito, Hiroshi Handa
Pageof 55